| ABSTRACT | 第4-5页 |
| CHAPTER ONE INTRODUCTION | 第10-11页 |
| CHAPTER TWO LITERATURE REVIEW | 第11-17页 |
| 2.1 TNF -α | 第11页 |
| 2.2 IL-21 | 第11-14页 |
| 2.3 Infliximab | 第14-15页 |
| 2.4 Etanercept | 第15页 |
| 2.5 Adalimumab | 第15-17页 |
| CHAPTER THREE- Study on Serum TNF-α and IL-21 level in Rheumatoid Arthritis | 第17-41页 |
| 3.0 Patients | 第17-19页 |
| 3.1 Method for TNF -α | 第19页 |
| 3.2 Statistics | 第19-20页 |
| 3.3 Serum TNF-α was significantly increased in the RA patients compared to the healthy people | 第20-21页 |
| 3.4 Correlation of TNF- α levels in the groups with disease activity | 第21-30页 |
| 3.5 The Plasma Levels of ESR, CRP, and DAS 28 Decreased After Treatment | 第30-35页 |
| 3.6 Patients and methods | 第35-37页 |
| 3.7 Method for IL-2128 | 第37-38页 |
| 3.8. Serum IL-21 was significantly increased in RA with history <1yr | 第38-39页 |
| 3.9 Correlation of IL-21 levels in the groups with disease activity | 第39-41页 |
| CHAPTER FOUR DISCUSSION | 第41-46页 |
| 4.0 The level of IL-21 increased in Early RA patients | 第41页 |
| 4.1 The level of TNF-alpha increased in RA patients | 第41-43页 |
| 4.2 The Plasma Levels of ESR, CRP,and DAS 28 Decreased After Treatment and TNF-α Increased After Treatment with TNF –α Blockers | 第43-44页 |
| 4.3 Correlation of TNF-α with Disease activity index | 第44-45页 |
| 4.4 Conclusion | 第45-46页 |
| REFERENCES | 第46-52页 |
| INTRODUCTION OF AUTHOR | 第52-53页 |
| ACKNOWLEDGEMENTS | 第53页 |
